# Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon

> **NCT00251238** · PHASE2 · COMPLETED · sponsor: **VSM Geneesmiddelen b.v.** · enrollment: 41 (actual)

## Conditions studied

- Raynaud Disease

## Interventions

- **DRUG:** Ginkgo biloba extract EGb 761

## Key facts

- **NCT ID:** NCT00251238
- **Lead sponsor:** VSM Geneesmiddelen b.v.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-03
- **Final completion:** 2006-04
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251238, "Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00251238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*